| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYCBP |
| Uniprot No | Q99417 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-103aa |
| 氨基酸序列 | AHYKAADSKREQFRRYLEKSGVLDTLTKVLVALYEEPEKPNSALDFLKHHLGAATPENPEIELLRLELAEMKEKYEAIVEENKKLKAKLAQYEPPQEEKRAE |
| 预测分子量 | 27.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Recombinant MYCBP Protein Induces Apoptosis in Cancer Cells via p53 Activation"**
*作者：Li et al. (2018)*
摘要：研究报道了重组MYCBP蛋白通过激活p53信号通路抑制肿瘤细胞增殖并诱导凋亡，为靶向MYC信号通路的抗癌治疗提供依据。
2. **"Expression and Purification of Functional MYCBP in E. coli for Structural Studies"**
*作者：Smith & Johnson (2020)*
摘要：成功在大肠杆菌中表达并纯化具有生物活性的重组MYCBP蛋白，通过X射线晶体学解析其三维结构，揭示其与MYC蛋白互作的关键结构域。
3. **"MYCBP Recombinant Protein Enhances Neuronal Differentiation in Stem Cells"**
*作者：Wang et al. (2019)*
摘要：发现重组MYCBP蛋白通过调控Wnt/β-catenin通路促进神经干细胞分化为成熟神经元，提示其在神经再生治疗中的潜在应用。
4. **"Functional Analysis of MYCBP in DNA Damage Response Using Recombinant Protein"**
*作者：Garcia et al. (2021)*
摘要：利用重组MYCBP蛋白证明其通过结合ATM激酶参与DNA损伤修复，为解析MYCBP在基因组稳定性中的作用机制提供实验证据。
(注：以上文献信息为示例性内容，实际文献需通过学术数据库检索确认。)
MYCBP (MYC-binding protein), also known as MYCBP2 or PAM (Primary microcephaly autosomal recessive protein 1), is a multifunctional E3 ubiquitin ligase implicated in regulating cellular processes such as neuronal development, cell proliferation, and tumorigenesis. It interacts directly with the MYC oncoprotein family (c-MYC, N-MYC, L-MYC), which are master transcription factors controlling cell cycle progression, metabolism, and apoptosis. MYCBP facilitates the ubiquitination and proteasomal degradation of MYC proteins, acting as a negative regulator to maintain MYC homeostasis. Dysregulation of this interaction is linked to MYC-driven cancers, where MYC overexpression promotes uncontrolled cell growth.
Recombinant MYCBP proteins are engineered using expression systems (e.g., E. coli, mammalian cells) to study its biochemical properties, structural motifs, and interaction networks. These proteins often include affinity tags (e.g., His, GST) for purification and detection. Key domains in MYCBP include the RING finger domain (critical for E3 ligase activity) and MYC-binding regions. Researchers use recombinant MYCBP to investigate its role in ubiquitination assays, MYC stability modulation, and pathways like Wnt/β-catenin or Notch signaling. Its involvement in neurodevelopmental disorders (e.g., microcephaly) and cancer metastasis has also spurred interest in therapeutic targeting. Structural studies of recombinant MYCBP have revealed binding interfaces with MYC and co-factors like USP28. which counteracts its degradative function. Current research explores small molecules to modulate MYCBP-MYC interactions, aiming to destabilize oncogenic MYC in tumors while sparing normal cells.
×
